Advances and prospects of theranostic nanoparticles in personalized medicine
Keywords:
nanoparticles, biomarker, nanotheranostics, biomolecules, medicationAbstract
Nanotheranostics, coordination appropriate to analytic alsohelpful capacity in one framework utilizingadvantages appropriate to nanotechnology, is very alluring inasmuchas customized medication. Since treating malignant growth is certainly not a one-size-fits-all situation, it expects treatment towards be adjusted towards patient's particular biomolecules. Customized alsoaccuracy medication (PM) does precisely that. It distinguishes biomarkers towards acquire a comprehension appropriate to conclusion alsothusly treatingparticular issue in view appropriate to exact finding. By prevalently usingextraordinary properties appropriate to nanoparticles towards accomplish biomarker distinguishing proof also medication conveyance, nanotheranostics can be applied towards painlessly find also target picture biomarkers also further convey treatment in light appropriate to biomarker dispersion. This is an enormous alsoconfident job theranostics should fill. In any case, as portrayed in this well-qualified assessment, current nanotechnology-based theranostics frameworks designed inasmuchas PM applications are not yet adequate. PM is a consistently developing field that will be a main impetus inasmuchas future disclosures in biomedicine, particularly malignant growth theranostics. In this article, writers take apartnecessities inasmuchas fruitfulnanotheranostics-based PM.
Downloads
References
Adams GP, Weiner LM. Monoclonal antibody therapy appropriate to cancer. Nat Biotechnol. 2005;23(9):1147–1157. [PubMed] [Google Scholar]
Akhter S, Ahmad MZ, Ahmad FJ, Storm G, Kok RJ. Gold nanoparticles in theranostic oncology: current state-of-the-art. Expert Opin Drug Deliv. 2012;9(10):1225–1243. [PubMed] [Google Scholar]
Alivisatos AP. Semiconductor clusters, nanocrystals, also quantum dots. Science. 1996;271(5251):933–937. [Google Scholar]
Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types appropriate to diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–511. [PubMed] [Google Scholar]
Bittner M, Meltzer P, Chen Y, et al. Molecular classification appropriate to cutaneous malignant melanoma by gene expression profiling. Nature. 2000;406(6795):536–540. [PubMed] [Google Scholar]
Carter PJ, Senter PD. Antibody–drug conjugates inasmuch as cancer therapy. Cancer J. 2008;14(3):154–169. [PubMed] [Google Scholar]
Chen XS. Introducing Theranostics Journal – from Editor-in-Chief. Theranostics. 2011;1:1–2. [PMC free article] [PubMed] [Google Scholar]
Chen XS. One year after a successful start appropriate to theranostics. Theranostics. 2012;2(1):1–2. [PMC free article] [PubMed] [Google Scholar]
Chikkaveeraiah BV, Bhirde AA, Morgan NY, Eden HS, Chen X. Electrochemical immunosensors inasmuch as detection appropriate to cancer protein biomarkers. ACS Nano. 2012;6(8):6546–6561. [PMC free article] [PubMed] [Google Scholar]
Choi KY, Jeon EJ, Yoon HY, et al. Theranostic nanoparticles based on PEGylated hyaluronic acid inasmuch as diagnosis, therapy also monitoring appropriate to colon cancer. Biomaterials. 2012;33(26):6186–6193. [PMC free article] [PubMed] [Google Scholar]
Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation appropriate to prognostic biomarkers in prostate cancer. Nature. 2001;412(6849):822–826. [PubMed] [Google Scholar]
Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohistochemistry (HercepTest) also fluorescence in situ hybridization (FISH) inasmuch as HER-2 in 426 breast carcinomas from 37 centres. J Pathol. 2003;199(4):418–423. [PubMed] [Google Scholar]
Eckelman WC, Reba RC, Kelloff GJ. Targeted imaging: an important biomarker for as understanding disease progression in era appropriate to personalized medicine. Drug Discov Today. 2008;13(17–18):748–759. [PubMed] [Google Scholar]
Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic anddiagnostic modalities. Adv Drug Deliv Rev. 2006;58(14):1456–1459. [PubMed] [Google Scholar]
Golub TR, Slonim DK, Tamayo P, et al. Molecular classification appropriate to cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286(5439):531–537. [PubMed] [Google Scholar]
Grzelczak M, Pérez-Juste J, Mulvaney P, Liz-Marzán LM. Shape control in gold nanoparticle synthesis. ChemSoc Rev. 2008;37(9):1783–1791. [PubMed] [Google Scholar]
Hamburg MA, Collins FS. path towards personalized medicine. N Engl J Med. 2010;363(4):301–304. [PubMed] [Google Scholar]
Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene. 2000;19(53):6102–6114. [PubMed] [Google Scholar]
Haynes CL. Nanosphere lithography: a versatile nanofabrication tool inasmuch as studies appropriate to size-dependent nanoparticle optics. J Phys Chem. 2001;105(24):5599–5611. [Google Scholar]
Hulteen JC, Treichel DA, Smith MT, Duval ML, Jensen TR, Van Duyne RP. Nanosphere lithography: size-tunable silver nanoparticle andsurface cluster arrays. J PhyChem B. 1999;103(19):3854–3863. [Google Scholar]
Liotta L, Petricoin E. Molecular profiling appropriate to human cancer. Nat Rev Genet. 2000;1(1):48–56. [PubMed] [Google Scholar]
Mura S, Couvreur P. Nanotheranostics for personalized medicine. Adv Drug Deliv Rev. 2012;64(13):1394–1416. [PubMed] [Google Scholar]
Pegram MD, Lipton A, Hayes DF, et al. Phase II study appropriate to receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory towards chemotherapy treatment. J ClinOncol. 1998;16(8):2659–2671. [PubMed] [Google Scholar]
Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits appropriate to human breast tumours. Nature. 2000;406(6797):747–752. [PubMed] [Google Scholar]
Rozenberg BA, Tenne R. Polymer-assisted fabrication appropriate to nanoparticles andnano-composites. Progress Polymer Sci. 2008;33(1):40–112. [Google Scholar]
Sadée W, Dai Z. Pharmacogenetics/genomics also personalized medicine. Hum Mol Genet. 2005;14(Spec no 2):R207–R214. [PubMed] [Google Scholar]
Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11(3):191–200. [PubMed] [Google Scholar]
Shao H, Min C, Issadore D, et al. Magnetic Nanoparticles andmicroNMR inasmuch as diagnostic applications. Theranostics. 2012;2(1):55–65. [PMC free article] [PubMed] [Google Scholar]
Sievers EL, Senter PD. Antibody–drug conjugates in cancer therapy. Annu Rev Med. 2013;64:15–29. [PubMed] [Google Scholar]
Swierczewska M, Lee S, Chen X. Moving theranostics from bench towards bedside in an interdisciplinary research team. TherDeliv. 2011;2(2):165–170. [PubMed] [Google Scholar]
Swierczewska M, Liu G, Lee S, Chen X. High-sensitivity nanosensors inasmuch as biomarker detection. ChemSoc Rev. 2012;41(7):2641–2655. [PMC free article] [PubMed] [Google Scholar]
Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab also chemotherapy as initial treatment inasmuch as metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408–1417. [PubMed] [Google Scholar]
Vogenberg FR, Isaacson Barash C, Pursel M. Personalized medicine: part 1: evolution and development into theranostics. P T. 2010;35(10):560–576. [PMC free article] [PubMed] [Google Scholar]
Wang LS, Chuang MC, Ho JA. Nano-theranostics – a review appropriate to recent publications. Int J Nanomedicine. 2012;7:4679–4695. [PMC free article] [PubMed] [Google Scholar]
Wang R, Billone PS, Mullett WM. Nanomedicine in action: an overview appropriate to cancer nanomedicine on market and in clinical trials. J Nanomat. 2013 doi: 10.1155/2013/629681. (Epub ahead appropriate to print) [CrossRef] [Google Scholar]
Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev. 2010;62(11):1064–1079. [PMC free article] [PubMed] [Google Scholar]
Xing Y, Chaudry Q, Shen C, et al. Bioconjugated quantum dots inasmuch as multiplexed also quantitative immunohistochemistry. Nat Protoc. 2007;2(5):1152–1165. [PubMed] [Google Scholar]
Zhang Y, Wang TH. Quantum dot enabled molecular sensing and diagnostics. Theranostics. 2012;2(7):631–654. [PMC free article] [PubMed] [Google Scholar]
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
